Processing

Please wait...

Settings

Settings

Goto Application

1. WO1999009164 - CODING SEQUENCE HAPLOTYPES OF THE HUMAN BRCA2 GENE

Publication Number WO/1999/009164
Publication Date 25.02.1999
International Application No. PCT/US1998/016905
International Filing Date 14.08.1998
Chapter 2 Demand Filed 02.03.1999
IPC
A61K 38/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
A61K 48/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
48Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
C07K 14/47 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
46from vertebrates
47from mammals
CPC
A61K 38/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
A61K 48/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
48Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
C07K 14/4703
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
46from vertebrates
47from mammals
4701not used
4702Regulators; Modulating activity
4703Inhibitors; Suppressors
C12Q 1/6806
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms
68involving nucleic acids
6806Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
C12Q 1/6886
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6883for diseases caused by alterations of genetic material
6886for cancer
Applicants
  • ONCORMED, INC. [US]/[US]
Inventors
  • MURPHY, Patricia, D.
  • WHITE, Marga, B.
  • RABIN, Mark, B.
  • OLSON, Sheri, J.
  • YOSHIKAWA, Matthew
  • JACKSON, Geoffrey, M.
  • ESKANDARI, Tara
  • SCHRYER, Brenda
  • PARK, Michael
Agents
  • HALLUIN, Albert, P.
Priority Data
09/071,71501.05.1998US
09/084,47122.05.1998US
60/055,78415.08.1997US
60/064,92607.11.1997US
60/065,36712.11.1997US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) CODING SEQUENCE HAPLOTYPES OF THE HUMAN BRCA2 GENE
(FR) HAPLOTYPES D'UNE SEQUENCE CODANTE DU GENE HUMAIN BRCA2
Abstract
(EN) Five DNA and protein sequences have been determined for the BRCA2 gene, as have been ten polymorphic sites and their rates of occurrence in the normal alleles of BRCA2. The sequences BRCA2(omi1-5) and the ten polymorphic sites will provide accuracy and reliability for genetic testing. One skilled in the art will be able to avoid misinterpretations of changes in the gene and/or protein sequence, determine the presence of a normal sequence, and of mutations of BRCA2. This invention is also related to a method of performing gene therapy with BRCA2(omi1-5) coding sequences or fragments thereof. This invention is further related to protein therapy with BRCA2(omi1-5) proteins or their functional equivalents.
(FR) Selon cette invention, on détermine cinq séquences d'ADN et de protéines pour le gène BRCA2, dix sites polymorphes ainsi que leurs taux d'occurrences dans les allèles normaux du BRCA2. Les séquences BRCA2(omi1-5) et les dix sites polymorphes permettront aux tests génétiques d'être précis et fiables. Les spécialistes pourront ainsi éviter les mauvaises interprétations des changements subis par le gène et/ou la séquence protéique, déterminer la présence d'une séquence normale, et des mutations de BRCA2. Cette invention concerne également un procédé permettant d'effectuer une thérapie génique avec les séquences codantes du BRCA2(omi1-5) ou des fragments de celles-ci. Par ailleurs, cette invention concerne une thérapie protéique effectuée avec les protéines BRCA2(omi1-5) ou leurs équivalents fonctionnels.
Related patent documents
EP2010175336This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.
Latest bibliographic data on file with the International Bureau